Cannabis Science Set to Release its First Line of European Products at Spannabis 2015, Taking Place in Barcelona, Spain from March 20th until the 22nd

USA - English

• USA - español

COLORADO SPRINGS, Colo., March 9, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce it is set to release its first line of European products that will feature Cannabis Science proprietary formulations developed in Spain and the Netherlands at Spannabis 2015, taking place in Barcelona, Spain from March 20^th until the 22^nd, the largest Cannabis conference in the world. Other European markets will follow as jurisdictional laws permit.

Spannabis is the largest cannabis conference in the world and has been held in Barcelona since 2004. Cannabis Science is pleased to exhibit for the first time at the internationally acclaimed conference to showcase its initial European product line. Dr. Mario Lap, President of Cannabis Science European Operations will be present. " We are delighted to be attending Spannabis and showcasing our products that have been in drug development pipeline for the last 2 years, after rigorous testing we are excited to show them to Spain and the rest of the world."

At the core of the new products are Cannabis Science's proprietary formulations that have been undergoing development in Spain and the Netherlands.

Mid-Tier Critical Ailment Application Usage (new formulations)

1.         CS-M4 – (Ingested and Topical formulations)

Applications: side effects chemo therapy, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis, infections, diabetes, manic depression and fibromyalgia.

2.         CS-M18 – (Ingested and Topical formulations)

Applications: side effects chemo therapy, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis, infections, diabetes, manic depression and fibromyalgia.  

3.         CS-ACCV – (Topical Formulations)

Applications: rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain.

4.         CS-CLDL – (Topical Formulations) whole plant based cannabinoid formulation

Applications: radiotherapy wounds, rheumatism, open wounds, sensitive and irritated skin.

5.         CS-CRRT – (Topical Formulations) whole plant based cannabinoid formulation

Applications: various skin complaints, wounds and eczema.

"This will be the first time Cannabis Science has publicly showcased products to a European audience. We are pushing to get the product line into the hands of people needing it most," said Mr. Raymond C. Dabney, President & CEO, Cannabis Science, Inc.

Catalonia has recently passed laws to introduce medical cannabis clubs in Spain under Spanish law.  Cannabis Science intends on leveraging its experience in regulatory frameworks to establish and be a driving force in the cultivation, research and development around extraction and helping the introduced regulatory measures co-exist within a developing larger European market. 

Cannabis Science is currently harvesting 40 Acres of cultivation facilities in Spain and is working aggressively to partner with patient organizations, public healthcare systems and private companies to expand its on-going commitments in the emerging market. 

About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Media Contact:

VAN STONE PUBLICITY
Carrol Van Stone
[email protected]
Tel: 304-671-0244

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
[email protected]
Tel: 1.888.889.0888

Dr. Mario S. Lap
Director & President of European Operations
[email protected]
Tel: 1.888.889.0888

www.cannabisscience.com

SOURCE Cannabis Science, Inc.